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Response to 'Orbital Wegener's granulomatosis as the initial presentation in a 9-year-old child'
We were interested to read the article by Dey et al. describing the ocular presentation of Wegener's granulomatosis in a child. 1 The authors considered corticosteroids to be the first line of treatment in this condition. This varies from the usual induction regimen, which is a combination of cyclophosphamide and corticosteroid.
Wegener's granulomatosis, often referred to as granulomatosis with polyangiitis, is a fatal disease, with mortality if untreated of 90% at two years. In 1973, Fauci and Wolff showed that a regimen that combined cyclophosphamide and prednisolone induced disease remission. 2 This combination was superior to corticosteroid treatment alone. Subsequent long-term experience has demonstrated that the cyclophosphamide and prednisolone regimen induces remission in 85 -90% of patients within two to six months. 3 More recently the introduction of the anti B-cell monoclonal antibody, rituximab, has provided an alternative induction therapy to cyclophosphamide or for use in cyclophosphamide-resistant disease. 4 It is currently recommended as an initial induction regimen only in those patients who have a contraindication to cyclophosphamide.
While single therapy with either corticosteroids or co-trimoxazole have had their advocates, current advice is that in treatment of limited disease combination therapy with corticosteroid and either methotrexate or cyclophosphamide should be used. Co-trimoxazole can be used as part of maintenance therapy to prevent Pneumocystis infection. 5 Once remission is achieved patients are then switched to maintenance immunosuppression such as methotrexate or azathioprine. Thus corticosteroids alone appear inferior for both induction and maintenance therapy. 
Authors' response to Meredith and Hull
We thank Meredith and Hull for the interest in our article about orbital Wegener's granulomatosis in a 9-year-old child as the initial presentation. 1 As stated in the article it is important for these patients to be managed by specialist centres which deal with paediatric immunological disease. The child after obtaining the diagnosis was referred to a specialist centre in which she was enrolled onto the European Vasculitis Study Group (EUVAS) Trial. She was randomized in receiving mycophenolate 750 mg b.d. together with prednisolone 1 mg/kg/day orally which was tapered over the course of weeks as per protocol.
Mycophenolate mofetil (MMF) is a prodrug that is hydrolysed to mycophenolic acid. The active metabolite mycophenolic acid reversibly inhibits inosin-monophosphate-dehydrogenase (IMDH), a key enzyme of de novo purine synthesis. Lymphocytes are key effector cells in ANCAassociated systemic vasculitis (AASV), whose proliferation and function relies almost exclusively on de novo purine synthesis whereas most other cells use the salvage pathway.
MMF appears to be an excellent alternative to cyclophosphamide for induction of remission in AASV because it has strong immunosuppressive potency combined with low toxicity profile. After 6 months she was commenced on azathioprine 75 mg a day together with prednisolone of a maintenance dose of 7.5 mg as per the protocol. She is currently in remission. The trial is ongoing and results are yet to be published.
In summary we agree with Meredith and Hull's observation that corticosteroids alone are inadequate for both the induction and continual remission of Wegener's granulomatosis.
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